ASSOCIATION OF TELOMERE LENGTH WITH SURVIVAL IN COLORECTAL CANCER PATIENTS: RESULTS FROM THE COLOCARE STUDY

Svenja Pauleck1, Richard M. Cawthon1, Biljana Gigic2, Christy A. Warby3, Jennifer Snitout4, Tengda Lin5, Jennifer Ose6, Anita R. Peoples7, Juergen Boehm1, Petra Schrott-King8, Torsten Koelsch9, Christopher I. Li, David Shibata3, Erin M. Siegel3, Jane C. Figueiredo8, Adetunji T. Tomo10, Martin Schneider1, Alexis B. Ulrich1, Cornelia M. Ulrich1, Sheetal Hardikar1,4

1University of Utah, Salt Lake City, Utah, USA; 2Niederberg University Hospital, Heidelberg, Germany; 3German Centre for Cardiovascular Research, Center HeidelbergDKFZ, Heidelberg, Germany; 4Fred Hutchinson Cancer Research Center, Seattle, Washington, USA; 5University of Tennessee Health Science Center, Memphis, Tennessee, USA; 6Poole MultiDisciplinary Clinical Center, A Roswell Park Institute. 7Flinders University, Flinders, Australia; 8Cancer Care Ontario, Ontario, Canada; 9German Cancer Research Center, Heidelberg, Germany; 10Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.

BACKGROUND
- Telomeres are repetitive nucleotide structures at the end of eukaryotic chromosomes. (Figure 1)
- Telomere length variation can cause chromosomal instability, thus influencing the risk and prognosis of several cancers.
- Several studies have demonstrated an association between telomere length and colorectal cancer (CRC) risk, though the relationship with colorectal cancer survival is less clear.
- Both longer and shorter telomeres have been previously reported to be associated with poorer survival in CRC patients.

Figure 1. Telomere structure.

Ref.: Doksani Y., Genes (Basel), 2019

METHODS

- **Participants (N=92)**: The ColoCare Study (ClinicalTrials.gov Identifier: NCT02328677) is a multi-center cohort of newly-diagnosed stage I-IV CRC patients recruited prior to surgery. As part of the study, clinicodemographic data, biospecimens and information on lifestyle factors, symptoms and health outcomes are collected at baseline and up to 5 years after diagnosis. N=92 colorectal cancer patients enrolled at the ColoCare Study site in Heidelberg, Germany, were included in the current analysis (Table 1).
- **Exposure assessment**: Baseline genomic DNA from blood leukocytes was extracted from eligible study participants. Telomere length (T) relative to a single copy gene (S) was measured in extracted DNA using the multiplex quantitative polymerase chain reaction.
- **Outcome assessment**: Time to event was computed as time from CRC surgery to either death or recurrence. Progression free survival (PFS) for each patient was defined as time to disease recurrence or death from any cause, while overall survival (OS) was defined as time to death from any cause.
- **Statistical analysis**: Hazard ratios (HR) and 95% confidence intervals (CIs) were computed for OS and PFS using Cox proportional hazards regression models, adjusting for confounders. Telomere length (T/S ratio) was log transformed to make the distribution approximately normal.

RESULTS

- Median T/S ratio for telomere length was 0.48 (0.31-0.94).
- Median follow up time for PFS was 65.2 months and for OS was 66.2 months.

**Progression-Free Survival (PFS)**
- When evaluated on a continuous scale, each unit decrease in the T/S ratio was associated with a 14% poorer survival in age- and sex-adjusted models (HR[95% CI] =1.14[0.22-5.88]), however the results did not reach statistical significance.
- K-M curves for PFS are shown in Figure 2.
- When categorized as quartiles of telomere length, we observed poorer survival for the shortest quartile compared to the longest in fully adjusted models, p-trend$_{pfs}$=0.88. (Table 2).
- Fully adjusted HRs for T/S ratio both as a continuous variable (after smoothing cubic splines) as well as by quartiles of telomere length are plotted in Figure 3.

**Overall Survival (OS)**
- HRs for telomere length quartiles presented a non-linear association with overall survival. In a fully adjusted model, we observed poorer OS in the shortest quartile of telomere length (HR[95% CI] =2.25[0.47-10.79]) (Table 2).

**Table 1. Clinicodemographic characteristics of study participants.**

<table>
<thead>
<tr>
<th>Participants (N=92)</th>
<th>Variable (mean ± SD) / N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>62.8 (±11.9)</td>
</tr>
<tr>
<td>Sex (Male)</td>
<td>67.4</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>26.2 (±3.6)</td>
</tr>
<tr>
<td>Smoking status (Ever)</td>
<td>65.2</td>
</tr>
<tr>
<td>Tumor site</td>
<td>Colon 51.1, Rectum 48.8</td>
</tr>
<tr>
<td>Tumor stage</td>
<td>I, II, III, IV</td>
</tr>
</tbody>
</table>

**Table 2. HR (95% CI) for PFS and OS by quartiles of telomere length.**

<table>
<thead>
<tr>
<th>T/S ratio quartile</th>
<th>Age/ sex adjusted</th>
<th>Fully adjusted $^a$</th>
<th>Age/ sex adjusted</th>
<th>Fully adjusted $^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1 shortest</td>
<td>1.37</td>
<td>3.58</td>
<td>0.86</td>
<td>2.25</td>
</tr>
<tr>
<td>Q2</td>
<td>1.12</td>
<td>1.86</td>
<td>1.01</td>
<td>2.02</td>
</tr>
<tr>
<td>Q3</td>
<td>0.83</td>
<td>1.64</td>
<td>0.90</td>
<td>2.46</td>
</tr>
<tr>
<td>Q4 reference</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
</tr>
</tbody>
</table>

$^a$Age, sex, BMI, smoking status, alcohol intake, supplement intake, NSAID use, physical activity, treatment, and tumor stage

Figure 2. Kaplan Meier survival curves for PFS comparing longer vs. shorter telomere length.

Figure 3. Fully adjusted HRs (95% CI) for PFS including telomere length as a continuous variable and categorized by quartiles among newly diagnosed stage I-IV colorectal cancer patients in the ColoCare Study.

CONCLUSIONS

- Our results suggest that individuals with shorter telomeres may have poorer progression-free and overall survival after colorectal cancer diagnosis.
- Larger populations are needed to further evaluate telomere length as a prognostic biomarker in colorectal cancer progression.

**Figure 1.** Telomere structure.

Ref.: Doksani Y., Genes (Basel), 2019

**Table 1.** Clinicodemographic characteristics of study participants.

**Table 2.** HR (95% CI) for PFS and OS by quartiles of telomere length.

**Figure 2.** Kaplan Meier survival curves for PFS comparing longer vs. shorter telomere length.

**Figure 3.** Fully adjusted HRs (95% CI) for PFS including telomere length as a continuous variable and categorized by quartiles among newly diagnosed stage I-IV colorectal cancer patients in the ColoCare Study.